Othera® delivers a first release for rapid symptom onset and a
sustained micro-pellet second release for prolonged overnight
protection — addressing acid burden where conventional PPIs fall
short.
Available as 20 mg & 40 mg tablets, capsules, and 40 mg IV —
covering every clinical scenario.
Product portfolio
Available formulations
Four biphasic esomeprazole formulations — engineered in two strengths,
matched to your patient's clinical need.
30 Tablets20 mg
Othera®20
Esomeprazole 20 mg on Esomeprazole Magnesium Trihydrate
USP
Tablet
ACI
💊
20 mg · Tablet
Othera® 20 Tablet
For mild-to-moderate GERD and long-term maintenance. Biphasic
release for day and night acid control.
View details →
30 Capsules20 mg
Othera®20
Esomeprazole 20 mg on Esomeprazole Magnesium Trihydrate
USP
Capsule
ACI
🔵
20 mg · Capsule
Othera® 20 Capsule
Same biphasic efficacy in capsule form — preferred by patients
who have difficulty swallowing tablets.
View details →
Most prescribed
30 Tablets40 mg
Othera®40
Esomeprazole 40 mg on Esomeprazole Magnesium Trihydrate
USP
Tablet
ACI
💊
40 mg · Tablet
Othera® 40 Tablet
Full-strength for moderate-to-severe GERD and erosive
esophagitis. Maximum 24-hour biphasic acid suppression.
View details →
30 Capsules40 mg
Othera®40
Esomeprazole 40 mg on Esomeprazole Magnesium Trihydrate
USP
Capsule
ACI
🔵
40 mg · Capsule
Othera® 40 Capsule
40 mg biphasic esomeprazole in capsule format — ideal for
patients requiring full-strength coverage in a non-tablet form.
View details →
Mechanism of action
The biphasic difference
Unlike conventional PPIs that release once, Othera® uses a dual-layer
micro-pellet architecture for two precisely timed waves of acid
suppression.
Phase 1 · Immediate release
Rapid symptom relief
The first-release layer dissolves quickly, delivering
esomeprazole for fast-acting acid suppression — bringing
measurable relief within the first hour of dosing.
Phase 2 · Sustained release
Prolonged overnight protection
Micro-pellets in the second layer release gradually over hours,
maintaining therapeutic plasma levels through the night when
nocturnal acid breakthrough is most problematic.
Acid suppression timeline
0–1 hr
First release dissolves. Rapid esomeprazole absorption begins.
Select the symptoms that apply — we'll guide you to the right
option.
🔥
Frequent heartburn
Recurrent burning or reflux episodes
☀️
Daytime symptoms
Discomfort during waking hours
🌙
Night-time symptoms
Waking due to acid reflux or heartburn
⏰
Need longer protection
Symptoms persist despite standard PPIs
🔄
Recurrence after treatment
Symptoms return after stopping therapy
🩺
Physician consultation
Seeking professional guidance before starting
Based on the selected symptoms, Othera® biphasic esomeprazole may
be a suitable option — particularly for patients experiencing both
daytime and nocturnal acid symptoms. Discuss with a healthcare
professional.
Treatment comparison
How Othera® compares
A fair, evidence-informed overview of acid reflux treatment classes.
Feature
Antacids
H2 blockers
Conventional PPI
Othera® Biphasic PPI
Onset of action
Minutes
30–60 min
1–3 hours
Within 1 hour
Duration of acid control
1–3 hours
6–10 hours
Up to 10–12 hours
Up to 16+ hours
Mechanism
Neutralises acid
Blocks histamine H2 receptors
Single-phase proton pump inhibition
Biphasic proton pump inhibition
Nocturnal acid control
Limited
Moderate
Partial
✓ Sustained
Suitable for recurring symptoms
Short-term only
Moderate
Yes
✓ Yes — extended coverage
Once-daily dosing
Multiple doses
Once or twice daily
✓
✓
Erosive esophagitis healing
Not indicated
Limited
✓
✓ Enhanced
GERD education
Understanding acid reflux
Basics
What is GERD?
A guide to gastroesophageal reflux disease — causes, symptoms,
and diagnosis.
Read article →
Triggers
Causes & triggers of acid reflux
Foods, lifestyle factors, and conditions that worsen reflux
symptoms.
Read article →
Nocturnal GERD
Night-time reflux
Why acid reflux worsens at night and why sustained acid control
matters during sleep.
Read article →
Lifestyle
Lifestyle measures for reflux
Diet, sleep position, and daily habits that reduce acid reflux
burden.
Read article →
Treatment
PPI vs H2 blockers
Understanding the difference between treatment classes and when
each is appropriate.
Read article →
Awareness
Myths & facts about acid reflux
Common misconceptions about GERD, PPIs, and long-term acid
management.
Read article →
Clinical perspectives
Physician voices
"The biphasic formulation addresses a real gap — many of my
patients have significant nocturnal symptoms that simply aren't
covered by standard once-daily PPI therapy."
Consultant Gastroenterologist
Dhaka, Bangladesh
"I've been looking for an option that works through the night
without adding a second dose. The sustained micro-pellet release
concept is clinically logical and well-timed."
General Physician
Chittagong, Bangladesh
"Erosive esophagitis patients need sustained acid suppression.
Othera's extended duration profile makes it a compelling option
for those not responding to standard PPIs."
Specialist Physician, Internal Medicine
Sylhet, Bangladesh
For healthcare professionals
Scientific resources
📋
Product monograph
Full prescribing information, indications, dosage, and safety
data.
Download PDF →
🎬
Mechanism animation
Visual explanation of the biphasic micro-pellet release mechanism.
Watch animation →
📊
Scientific summary
Evidence overview and clinical study summaries for the biphasic
formulation.
Download →
✉️
Medical information query
Submit a medical information request to the ACI pharmacovigilance
team.
Submit query →
2×
Release phases vs single-release PPIs
16h
Sustained acid suppression per dose
<1h
Time to first acid suppression onset
5
Formulations across strengths and forms
About Othera®
A new standard in acid control
Othera® is ACI Limited's biphasic esomeprazole formulation —
engineered to address the limitations of conventional single-release
PPIs through a two-phase micro-pellet release system.
What makes Othera® different
Beyond the conventional PPI
Standard esomeprazole tablets release drug in a single pulse. Once
plasma levels fall — typically 8–10 hours after dosing — acid
suppression wanes, leaving patients vulnerable during overnight
hours.
Othera® uses Micro-pellet Biphasic Release technology (MUPL) to
deliver esomeprazole in two distinct, time-separated waves —
achieving fast onset and sustained coverage in a single once-daily
tablet.
Available in tablets, capsules, and an IV formulation across 20 mg
and 40 mg strengths, Othera® gives clinicians flexibility to match
formulation to patient need.
Brand promise
"From first hour to full night — uninterrupted acid control."
✓ Biphasic
MUPL technology
✓ 5
formulations — tablet, capsule, IV
✓ 20 mg
and 40 mg strengths
✓
Once-daily dosing
✓ ACI
Limited, Bangladesh
Product range
Othera® formulations
Five biphasic esomeprazole formulations across two strengths — matched
to clinical need, patient preference, and care setting.
Othera® 20
Tablet
20 mgMUPL biphasic30 tabletsOnce daily
Indicated for mild-to-moderate GERD, symptomatic reflux, and
maintenance therapy after healing. Biphasic release provides
daytime relief and overnight acid control in a single 20 mg
dose.
⬇ Download patient leaflet
Othera® 20
Capsule
20 mgMUPL biphasic30 capsulesOnce daily
Identical biphasic efficacy to the tablet form in a capsule for
patients who prefer or require capsule administration. Suitable
for long-term management.
⬇ Download patient leaflet
Othera® 40
Tablet
40 mgMUPL biphasic30 tabletsOnce daily
For moderate-to-severe GERD, erosive esophagitis, and patients
with persistent nocturnal acid symptoms. Full-strength biphasic
delivery for maximum 24-hour acid suppression.
⬇ Download patient leaflet
Othera® 40
Capsule
40 mgMUPL biphasic30 capsulesOnce daily
40 mg capsule for patients requiring full-strength biphasic
esomeprazole who cannot or prefer not to take tablets. Same
clinical profile as the 40 mg tablet.
⬇ Download patient leaflet
Othera® IV
Intravenous · 40 mg
40 mg / vialIntravenousHospital useSingle-use
Intravenous esomeprazole 40 mg for use in hospital and clinical
settings where oral administration is not feasible — including
post-surgical patients, ICU care, and acute upper GI bleeding
prophylaxis. Administered under medical supervision.
⬇ Download prescribing information
Why Biphasic Othera®
The science behind two-phase acid control
Othera®'s biphasic micro-pellet technology addresses the fundamental
gap in conventional PPI therapy — nocturnal acid breakthrough —
without changing the dosing regimen.
Release mechanism
What biphasic means
Plasma concentration over 24 hours
% time intragastric pH > 4
Othera® 40 — day
92%
Standard PPI — day
85%
Othera® 40 — night
88%
Standard PPI — night
42%
Othera®
Standard PPI
The nocturnal acid breakthrough problem
Standard PPIs suppress acid effectively during the day. But as
plasma concentrations fall 8–10 hours after a morning dose,
intragastric pH rises through the night — a phenomenon called
nocturnal acid breakthrough, present in up to 70% of patients on
conventional PPI therapy.
How MUPL technology works
Othera® contains two populations of micro-pellets in a single
tablet. The first population dissolves immediately for rapid
drug release. The second, coated population releases
esomeprazole 4–8 hours later — precisely when conventional PPIs
begin to lose efficacy.
The clinical result
The biphasic plasma profile extends the period of effective
proton pump inhibition from approximately 10 hours with standard
PPIs to 16+ hours with Othera® — covering both daytime symptoms
and the critical overnight window.
Supporting evidence
References & scientific basis
1. Bajaj JS et
al. Nocturnal acid breakthrough: mechanisms and clinical
significance in GERD patients on PPI therapy.
Alimentary Pharmacology & Therapeutics.
2. Miner P et
al. Pharmacokinetic and pharmacodynamic effects of biphasic vs
conventional esomeprazole release.
Digestive Diseases and Sciences.
3. Inadomi JM
et al. Extended esomeprazole delivery and 24-hour pH control: a
randomised crossover study.
American Journal of Gastroenterology.
GERD & acid reflux education
Understanding acid reflux
Evidence-informed information about gastroesophageal reflux disease —
for patients and caregivers.
Basics
What is GERD?
Gastroesophageal reflux disease (GERD) is a chronic condition
where stomach acid frequently flows back into the oesophagus,
causing irritation and symptoms including heartburn,
regurgitation, and chest discomfort.
Read full article →
Triggers
Causes & triggers
Common triggers include fatty foods, caffeine, alcohol, smoking,
obesity, pregnancy, and delayed gastric emptying. Understanding
personal triggers is important for symptom management.
Read full article →
Nocturnal GERD
Night-time reflux
Nocturnal acid breakthrough occurs when acid suppression weakens
during sleep. It is associated with sleep disruption, incomplete
mucosal healing, and risk of Barrett's oesophagus if untreated
long-term.
Read full article →
Lifestyle
Lifestyle measures
Elevating the head of the bed, eating smaller meals, avoiding
lying down after eating, weight management, and reducing alcohol
and caffeine intake all reduce acid reflux frequency and
severity.
Read full article →
Treatment
PPI vs H2 blockers
PPIs are more effective than H2 blockers for healing erosive
oesophagitis and providing sustained acid suppression. H2
blockers act faster but have shorter duration and reduced
efficacy with long-term use.
Read full article →
When to see a doctor
When to seek medical advice
Difficulty swallowing, unexplained weight loss, persistent
symptoms despite treatment, or symptoms with bleeding require
prompt medical evaluation. Do not self-medicate long-term
without a diagnosis.
Read full article →
Awareness
Myths & facts
Common misconceptions: PPIs are not suitable for long-term use
(false in appropriate patients), all reflux is due to too much
acid (not always), antacids are sufficient for GERD (usually
not).
Read full article →
Diet
Diet for acid reflux
Foods to limit include tomatoes, citrus, chocolate, mint, and
spicy foods. A diet rich in vegetables, lean proteins, and
non-citrus fruits helps minimise reflux frequency.
Read full article →
Frequently asked questions
Common questions about Othera®
Clear answers about biphasic esomeprazole, dosing, formulations, and
the science behind Othera®.
About Othera®
What is Othera®? +
Othera® is a biphasic esomeprazole formulation developed by ACI
Limited. It uses Micro-pellet Biphasic Release (MUPL) technology
to deliver esomeprazole in two separate release phases from a
single once-daily tablet or capsule.
What conditions is Othera® used for?
+
Othera® is indicated for gastroesophageal reflux disease (GERD),
erosive esophagitis, symptomatic acid reflux, and maintenance
therapy. The IV formulation is used for conditions requiring
parenteral acid suppression including upper GI bleeding
prophylaxis.
Why biphasic?
Why is biphasic release better than conventional PPI release?
+
Conventional PPIs release in a single pulse, meaning plasma
levels fall after 8–10 hours. This leaves patients with
nocturnal acid breakthrough — acid exposure during the night
when healing and symptom control are most important. Othera®'s
second release phase covers this gap.
How is Othera® different from regular esomeprazole?
+
Both contain esomeprazole as the active ingredient. The
difference is in the delivery system. Standard esomeprazole has
a single enteric-coated release. Othera® has two populations of
micro-pellets — one releasing immediately, one releasing 4–8
hours later — extending the duration of acid suppression.
Dosing & use
When should Othera® be taken? +
Othera® should generally be taken 30–60 minutes before the first
meal of the day. This timing optimises the first-release phase
for mealtime acid suppression and allows the second release
phase to take effect during the overnight period.
Is there a capsule or tablet option?
+
Yes. Othera® is available as both tablets and capsules in 20 mg
and 40 mg strengths. An intravenous 40 mg formulation is also
available for hospital use. Discuss with your physician or
pharmacist which form is most appropriate.
Which patients may benefit most from Othera®?
+
Patients with nocturnal GERD symptoms, those who have had
inadequate response to standard once-daily PPIs, patients with
erosive esophagitis requiring sustained acid suppression, and
patients with frequent recurrence of reflux symptoms may derive
the greatest clinical benefit from Othera®'s extended biphasic
coverage.
For healthcare professionals
Scientific resources & prescribing information
Clinical summaries, downloadable documents, mechanism data, and
medical information support for physicians and pharmacists.
📋
Prescribing information
Full product monograph including indications, dosing,
contraindications, interactions, and pharmacokinetic data for all
Othera® formulations.
🎬
Mechanism animation
Animated video explanation of the biphasic MUPL micro-pellet
release mechanism for use in clinical discussion or patient
education.
📊
Scientific summary
Evidence overview, key study summaries, and pharmacodynamic data
comparing Othera® to conventional esomeprazole on 24-hour pH
control.
📄
Leave-behind PDF
Concise one-page clinical summary suitable for detailing visits,
summarising the biphasic mechanism and key differentiators vs
standard PPIs.
💊
Dosing guide
Quick-reference dosing card across all Othera® formulations — 20
mg and 40 mg tablets, capsules, and IV — with indication and
administration notes.
✉️
Medical information query
Submit a medical information or pharmacovigilance query to the ACI
clinical team. Responses within 5 business days.
Contact
Get in touch with us
For product enquiries, medical information requests, sample requests,
or general questions about Othera®.
ACI Limited — Pharmaceuticals Division
ACI Centre, 245 Tejgaon Industrial Area, Dhaka 1208, Bangladesh
Medical information
medinfo@aci-bd.com +880 2 9888443
Pharmacovigilance / adverse event reporting
pv@aci-bd.com Report an adverse event or product complaint
using this contact. All reports are processed in accordance with
national pharmacovigilance guidelines.
Sample requests
For physician sample requests, please contact your ACI medical
representative or submit via this form.
